ArticleWorld journal of nuclear medicine2025
A Rare Case of Cystic Angiomatosis Involving the Bones: Our Experience and Review of Literature.
Article in World journal of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cystic angiomatosis (CA) is a rare, benign, multifocal disorder of mixed lesions (lytic, sclerotic) developed due to maldeveloped lymphatic and vascular systems. In majority of cases, it is identified fortuitously and mimicked as metastatic malignant lesions. In such cases, differential diagnosis followed by treatment is identified to be critical for stabilizing the disease and its prognosis. We reported a case of a 24-year-old female who presented to our center with complaints of lower back ache (∼4-6 weeks), intermittent pain in the abdomen, and occasional dyspnea on exertion. Imaging studies revealed mild lytic lesions and small-sized cysts in the spine, bones, and spleen. Investigations confirmed CA and follow-up treatment was given using zoledronic acid (4 mg/intravenous) every 3 months to stabilize the bone lesions. CA is a heterogeneous disease with unpredictable progression and uncertain treatment. So, it is highly recommended to disseminate research findings of all such rare cases to find any new pathophysiological findings and establish an effective treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.